Cannabis
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Cannabis and Cannabis-derived Products (e.g., Sativex) |
| FDA Approval | Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment |
| Used for | Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects |
| Clinical Trial Phase | Phase 2 trial for glioblastoma with Sativex combined with temozolomide |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products. |
| OS without | Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months) |
| OS with | Sativex combined with dose-intense temozolomide: Median survival exceeded 550 days (over 18 months) |
| PFS without | Not specified |
| PFS with | Not specifically mentioned; research primarily focused on overall survival and symptomatic relief |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 1 |
| Toxicity Explanation | The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider. |
Notes: In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.
From Ben Williams Book: Not specified
Loading comments...
